Steven P Rowe

List of Publications by Year in descending order

298 papers	7,983 citations	61687 45 h-index	78623 77 g-index
299 all docs	299 docs citations	299 times ranked	6846 citing authors

#	Article	IF	Citations
1	Neoadjuvant Nivolumab in Patients with High-risk Nonmetastatic Renal Cell Carcinoma. European Urology Oncology, 2022, 5, 113-117.	2.6	30
2	New imaging modalities to consider for men with prostate cancer on active surveillance. World Journal of Urology, 2022, 40, 51-59.	1.2	11
3	The European Association of Urology Biochemical Recurrence Risk Groups Predict Findings on PSMA PET in Patients with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy. Journal of Nuclear Medicine, 2022, 63, 248-252.	2.8	13
4	¹⁸F-DCFPyL PET Acquisition, Interpretation, and Reporting: Suggestions After Food and Drug Administration Approval. Journal of Nuclear Medicine, 2022, 63, 855-859.	2.8	12
5	Imaging of Cancer Immunotherapy: Response Assessment Methods, Atypical Response Patterns, and Immune-Related Adverse Events, From theAJRSpecial Series on Imaging of Inflammation. American Journal of Roentgenology, 2022, 218, 940-952.	1.0	5
6	No major impact of prescribed CAD drugs on myocardial perfusion uptake derived by [82]rubidium PET. Journal of Nuclear Cardiology, 2022, 29, 2863-2865.	1.4	0
7	11C-Para-aminobenzoic acid PET imaging of S. aureus and MRSA infection in preclinical models and humans. JCI Insight, 2022, 7, .	2.3	11
8	Changing Threshold-Based Segmentation Has No Relevant Impact on Semi-Quantification in the Context of Structured Reporting for PSMA-PET/CT. Cancers, 2022, 14, 270.	1.7	8
9	Acute axillary lymphadenopathy detected shortly after COVID-19 vaccination found to be due to newly diagnosed metastatic melanoma. Radiology Case Reports, 2022, 17, 878-880.	0.2	5
10	[18F]DCFPyL PET/CT for Imaging of Prostate Cancer. Nuklearmedizin - NuclearMedicine, 2022, 61, 240-246.	0.3	12
11	Visualization of Tumor Heterogeneity in Advanced Medullary Thyroid Carcinoma by Dual-Tracer Molecular Imaging. Clinical Nuclear Medicine, 2022, 47, 651-652.	0.7	6
12	Hematotoxicity and Nephrotoxicity in Prostate Cancer Patients Undergoing Radioligand Therapy with [177Lu]Lu-PSMA I&T. Cancers, 2022, 14, 647.	1.7	16
13	SPECT and PET Radiotracers in Renal Imaging. Seminars in Nuclear Medicine, 2022, 52, 406-418.	2.5	10
14	Novel Imaging Methods for Renal Mass Characterization: A Collaborative Review. European Urology, 2022, 81, 476-488.	0.9	44
15	Piflufolastat F 18-PET/CT in prostate cancer patients: An analysis of OSPREY (Cohorts A and B) standardized uptake value (SUV) results stratified by PSA and gleason score.. Journal of Clinical Oncology, 2022, 40, 35-35.	0.8	0
16	High SUVs Have More Robust Repeatability in Patients with Metastatic Prostate Cancer: Results from a Prospective Test-Retest Cohort Imaged with ¹⁸F-DCFPyL. Molecular Imaging, 2022, 2022, 7056983.	0.7	6
17	What Can Wonder Woman Teach Radiologists?. Journal of the American College of Radiology, 2022, 19, 314-315.	0.9	0
18	Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3269-3276.	3.3	25

#	Article	IF	Citations
19	A Series of PSMA-Targeted Near-Infrared Fluorescent Imaging Agents. Biomolecules, 2022, 12, 405.	1.8	1
20	Training on Reporting and Data System (RADS) for Somatostatin-Receptor Targeted Molecular Imaging Can Reduce the Test Anxiety of Inexperienced Readers. Molecular Imaging and Biology, 2022, , 1.	1.3	2
21	Impact of Tumor Burden on Normal Organ Distribution in Patients Imaged with CXCR4-Targeted [68Ga]Ga-PentixaFor PET/CT. Molecular Imaging and Biology, 2022, 24, 659-665.	1.3	17
22	¹⁷⁷Luâ€PSMA radioligand therapy effectiveness in metastatic castrationâ€resistant prostate cancer: An updated systematic review and metaâ€analysis. Prostate, 2022, 82, 826-835.	1.2	20
23	Diagnostic performance of IQÂ·SPECT with high-speed scanning: A preliminary quality control study in obese patients. Journal of Nuclear Cardiology, 2022, 29, 3443-3449.	1.4	1
24	More From Mooreâ€™s Law: The Journey to Toy Story and Implications for Radiology. Journal of the American College of Radiology, 2022, 19, 592-593.	0.9	1
25	Predictors of ¹⁸F-DCFPyL PET/CT Positivity in Patients with Biochemical Recurrence of Prostate Cancer After Local Therapy. Journal of Nuclear Medicine, 2022, 63, 1184-1190.	2.8	12
26	Molecular imaging in oncology: Current impact and future directions. Ca-A Cancer Journal for Clinicians, 2022, 72, 333-352.	157.7	106
27	Rechallenge With Additional Doses of 177Lu-DOTATOC After Failure of Maintenance Therapy With Cold Somatostatin Analogs. Clinical Nuclear Medicine, 2022, Publish Ahead of Print, .	0.7	2
28	Interobserver Agreement Rates on Fibroblast Activation Protein Inhibitorâ€“Directed Molecular Imaging and Therapy. Clinical Nuclear Medicine, 2022, 47, 512-516.	0.7	9
29	Podcasts and Radiology: Promoting Education and the Doctor-Patient Relationship through Storytelling. Journal of the American College of Radiology, 2022, , .	0.9	0
30	Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancer. Medical Oncology, 2022, 39, 63.	1.2	6
31	What does it take to be the best university or hospital? Research is the key and money matters. Clinical Imaging, 2022, 88, 1-3.	0.8	0
32	The future of radiology: What if artificial intelligence is really as good as predicted?. Diagnostic and Interventional Imaging, 2022, 103, 385-386.	1.8	16
33	Piflufolastat F-18 (¹⁸F-DCFPyL) for PSMA PET imaging in prostate cancerâ€¯. Expert Review of Anticancer Therapy, 2022, 22, 681-694.	1.1	9
34	Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [177Lu]Lu-PSMA I&T during long-term follow-up. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 4262-4270.	3.3	18
35	Renal oncocytoma: a challenging diagnosis. Current Opinion in Oncology, 2022, 34, 243-252.	1.1	3
36	Piflufolastat F 18-PET/CT in patients with prostate cancer: An analysis of OSPREY (cohorts A and B) standardized uptake value (SUV) results stratified by PSA and Gleason score.. Journal of Clinical Oncology, 2022, 40, 5024-5024.	0.8	1

#	Article	IF	Citations
37	In Vivo Functional Assessment of Sodium-Glucose Cotransporters (SGLTs) Using [¹⁸F]Me4FDG PET in Rats. Molecular Imaging, 2022, 2022, .	0.7	1
38	Prostate-specific membrane antigen PET response associates with radiographic progression-free survival following stereotactic ablative radiation therapy in oligometastatic castration-sensitive prostate cancer.. Journal of Clinical Oncology, 2022, 40, 5011-5011.	0.8	2
39	Implementation of cinematic rendering of gastric masses into clinical practice: a pictorial review. Abdominal Radiology, 2022, 47, 3386-3393.	1.0	7
40	Cost-effectiveness Analysis of 99mTc-sestamibi SPECT/CT to Guide Management of Small Renal Masses. European Urology Focus, 2021, 7, 827-834.	1.6	16
41	How to Hire the Best People and Inspire Performance: Lessons for Radiology. Journal of the American College of Radiology, 2021, 18, 133-134.	0.9	2
42	Cinematic rendering enhancements to virtual bronchoscopy: assessment of emergent tracheal pathology. Emergency Radiology, 2021, 28, 193-199.	1.0	2
43	Connecting With Patients: The Rapid Rise of Voice Right Now. Journal of the American College of Radiology, 2021, 18, 627-629.	0.9	1
44	Clinician-Scientists: Can They Survive in the Modern Era?. Journal of the American College of Radiology, 2021, 18, 192-197.	0.9	2
45	CTâ€based assessment of body composition following neoadjuvant chemohormonal therapy in patients with castrationâ€naÃ¯ve oligometastatic prostate cancer. Prostate, 2021, 81, 127-134.	1.2	9
46	Role of ¹⁸F-Fluciclovine and Prostate-Specific Membrane Antigen PET/CT in Guiding Management of Oligometastatic Prostate Cancer: AJR Expert Panel Narrative Review. American Journal of Roentgenology, 2021, 216, 851-859.	1.0	13
47	The Age of Artificial Intelligence: Does â€œWhyâ€•Still Matter?. Journal of the American College of Radiology, 2021, 18, 87-89.	0.9	1
48	Leadership: Delivering Success by Building Dynamic Teams. Journal of the American College of Radiology, 2021, 18, 457-458.	0.9	1
49	High Interobserver Agreement for the Standardized Reporting System SSTR-RADS 1.0 on Somatostatin Receptor PET/CT. Journal of Nuclear Medicine, 2021, 62, 514-520.	2.8	11
50	Imaging a Feverâ€"Redefining the Role of 2-deoxy-2-[18F]Fluoro-D-Glucoseâ€"Positron Emission Tomography/Computed Tomography in Fever of Unknown Origin Investigations. Clinical Infectious Diseases, 2021, 72, 1279-1286.	2.9	21
51	Detection of Early Progression with ¹⁸F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy. Journal of Nuclear Medicine, 2021, 62, 1270-1273.	2.8	6
52	Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigenâ€"Targeted ¹⁸F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide. Journal of Nuclear Medicine, 2021, 62, 1430-1437.	2.8	24
53	Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study. Clinical Cancer Research, 2021, 27, 3674-3682.	3.2	179
54	First-in-human neuroimaging of soluble epoxide hydrolase using [18F]FNDP PET. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3122-3128.	3.3	6

#	Article	IF	Citations
55	E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1626-1638.	3.3	188
56	A systematic review of imaging studies of human brown adipose tissue. Annals of the New York Academy of Sciences, 2021, 1495, 5-23.	1.8	2
57	PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) with biochemically recurrent prostate cancer (PCa): A phase III study (CONDOR)â€"A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth.. Journal of Clinical Oncology, 2021, 39, 33-33.	0.8	0
58	A prospective phase II/III study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A subanalysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging.. Journal of Clinical Oncology, 2021, 39, 32-32.	0.8	2
59	Cinematic rendering of CT angiography for visualization of complex vascular anatomy after hybrid endovascular aortic aneurysm repair. Emergency Radiology, 2021, 28, 839-843.	1.0	8
60	CXCR4-Directed PET/CT in Patients with Newly Diagnosed Neuroendocrine Carcinomas. Diagnostics, 2021, 11, 605.	1.3	18
61	Imaging of Fibroblast Activation Protein in Cancer Xenografts Using Novel (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine-Based Small Molecules. Journal of Medicinal Chemistry, 2021, 64, 4059-4070.	2.9	22
62	Process validation, current good manufacturing practice production, dosimetry, and toxicity studies of the carbonic anhydrase IX imaging agent [111 In]Inâ€XYIMSRâ€01 for phase I regulatory approval. Journal of Labelled Compounds and Radiopharmaceuticals, 2021, 64, 243-250.	0.5	2
63	Generational and Tech Shifts: A Decade of Digital Transformation in Service. Journal of the American College of Radiology, 2021, 18, 425-427.	0.9	1
64	Testicular ultrasound underestimates the size of small testicular masses: a radiologicâ€"pathologic correlation study. World Journal of Urology, 2021, 39, 3399-3405.	1.2	5
65	Imaging Enterobacterales infections in patients using pathogen-specific positron emission tomography. Science Translational Medicine, 2021, 13, .	5.8	49
66	Effect of Point-Spread Function Reconstruction for Indeterminate PSMA-RADS-3A Lesions on PSMA-Targeted PET Imaging of Men with Prostate Cancer. Diagnostics, 2021, 11, 665.	1.3	6
67	Theranostics in Oncologyâ€"Thriving, Now More than Ever. Diagnostics, 2021, 11, 805.	1.3	3
68	[18F]FDG-labelled stem cell PET imaging in different route of administrations and multiple animal species. Scientific Reports, 2021, 11, 10896.	1.6	11
69	Cellular and Molecular Imaging with SPECT and PET in Brain Tumors. Radiologic Clinics of North America, 2021, 59, 363-375.	0.9	5
70	Artificial intelligence in single photon emission computed tomography (SPECT) imaging: a narrative review. Annals of Translational Medicine, 2021, 9, 820-820.	0.7	11
71	PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) withbiochemically recurrent prostate cancer (PCa): A phase 3 study (CONDOR)â€"A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth.. Journal of Clinical Oncology, 2021, 39, 5023-5023.	0.8	1
72	A prospective phase 2/3 study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A sub-analysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging.. Journal of Clinical Oncology, 2021, 39, e17003-e17003.	0.8	0

#	Article	IF	Citations
73	Prostate-specific Membrane Antigen PET in Prostate Cancer. Radiology, 2021, 299, 248-260.	3.6	38
74	Applications of artificial intelligence in oncologic 18F-FDG PET/CT imaging: a systematic review. Annals of Translational Medicine, 2021, 9, 823-823.	0.7	32
75	SPECTnet: a deep learning neural network for SPECT image reconstruction. Annals of Translational Medicine, 2021, 9, 819-819.	0.7	14
76	The Entrepreneurial Mind-Set: A Framework for Problem-Solving and Creativity at Work and in Life. Journal of the American College of Radiology, 2021, 18, 764-765.	0.9	1
77	Artificial intelligence in molecular imaging: at the crossroads of revolutions in medical diagnosis. Annals of Translational Medicine, 2021, 9, 817-817.	0.7	7
78	Narrative review of generative adversarial networks in medical and molecular imaging. Annals of Translational Medicine, 2021, 9, 821-821.	0.7	19
79	64Cu-PSMA-BCH: a new radiotracer for delayed PET imaging of prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 4508-4516.	3.3	10
80	A three-stage, deep learning, ensemble approach for prognosis in patients with Parkinsonâ€™s disease. EJNMMI Research, 2021, 11, 52.	1.1	25
81	A bicentric retrospective analysis of clinical utility of 18F-fluciclovine PET in biochemically recurrent prostate cancer following primary radiation therapy: is it helpful in patients with a PSA rise less than the Phoenix criteria?. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 4463-4471.	3.3	9
82	Disrupting the Childcare Industry: Support for Early Career Radiologists and Our Leadership Pipeline. Journal of the American College of Radiology, 2021, 18, 884-886.	0.9	0
83	Reply by Authors. Journal of Urology, 2021, 206, 61-61.	0.2	2
84	Re: Patrick D. McGillivray, Daiki Ueno, Aydin Pooli, et al. Distinguishing Benign Renal Tumors with an Oncocytic Gene Expression (ONEX) Classifier. Eur Urol 2021;79:107â€“11. European Urology, 2021, 80, e20-e21.	0.9	0
85	A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177â€“labeled Prostate-specific Membrane Antigenâ€“targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer. European Urology, 2021, 80, 82-94.	0.9	53
86	Exceptional response to the ALK and ROS1 inhibitor lorlatinib and subsequent mechanism of resistance in relapsed ALK F1174L-mutated neuroblastoma. Journal of Physical Education and Sports Management, 2021, 7, a006064.	0.5	16
87	A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with ¹⁸ F-DCFPyL in Prostate Cancer Patients (OSPREY). Journal of Urology, 2021, 206, 52-61.	0.2	180
88	Empowering Women of Color to Lead and Succeed. Journal of the American College of Radiology, 2021, 18, 1216-1218.	0.9	0
89	Neuroendocrine Tumor Theranostics: An Update and Emerging Applications in Clinical Practice. American Journal of Roentgenology, 2021, 217, 495-506.	1.0	6
90	Surviving and Thriving in a Black Swan Event. Journal of the American College of Radiology, 2021, 18, 1369-1370.	0.9	0

#	Article	IF	Citations
91	PET Imaging for Prostate Cancer. Radiologic Clinics of North America, 2021, 59, 801-811.	0.9	10
92	â€œBrother, Can You Spare a Dime?â€•An Introduction to Philanthropy and Fundraising. Journal of the American College of Radiology, 2021, 18, 1466-1468.	0.9	2
93	Prostate Cancer Theranostics. , 2021, , 1117-1130.		0
94	Current and future perspectives on functional molecular imaging in nephro-urology: theranostics on the horizon. Theranostics, 2021, 11, 6105-6119.	4.6	13
95	Measurement of PET Quantitative Bias In Vivo. Journal of Nuclear Medicine, 2021, 62, 732-737.	2.8	3
96	Entrepreneurship as a Force for Good. Journal of the American College of Radiology, 2021, , .	0.9	0
97	Whole-Body [18F]FDG PET/CT Can Alter Diagnosis in Patients with Suspected Rheumatic Disease. Diagnostics, 2021, 11, 2073.	1.3	3
98	Dynamic PET-facilitated modeling and high-dose rifampin regimens for Staphylococcus aureus orthopedic implantâ€“associated infections. Science Translational Medicine, 2021, 13, eabl6851.	5.8	16
99	A Clinical Approach to Multimodality Imaging in Pulmonary Hypertension. Frontiers in Cardiovascular Medicine, 2021, 8, 794706.	1.1	6
100	The Number of Frames on ECG-Gated 18F-FDG Small Animal PET Has a Significant Impact on LV Systolic and Diastolic Functional Parameters. Molecular Imaging, 2021, 2021, 1-8.	0.7	2
101	Recent paradigm shifts in molecular cardiac imagingâ€”Establishing precision cardiology through novel 18F-labeled PET radiotracers. Trends in Cardiovascular Medicine, 2020, 30, 11-19.	2.3	19
102	Semiquantitative Parameters in PSMA-Targeted PET Imaging with [18F]DCFPyL: Intrapatient and Interpatient Variability of Normal Organ Uptake. Molecular Imaging and Biology, 2020, 22, 181-189.	1.3	14
103	Prospective Evaluation of PSMA-Targeted ¹⁸F-DCFPyL PET/CT in Men with Biochemical Failure After Radical Prostatectomy for Prostate Cancer. Journal of Nuclear Medicine, 2020, 61, 58-61.	2.8	61
104	Semiquantitative Parameters in PSMA-Targeted PET Imaging with [18F]DCFPyL: Impact of Tumor Burden on Normal Organ Uptake. Molecular Imaging and Biology, 2020, 22, 190-197.	1.3	27
105	High Availability of the Î±7-Nicotinic Acetylcholine Receptor in Brains of Individuals with Mild Cognitive Impairment: A Pilot Study Using ¹⁸F-ASEM PET. Journal of Nuclear Medicine, 2020, 61, 423-426.	2.8	22
106	A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancer. Prostate Cancer and Prostatic Diseases, 2020, 23, 184-193.	2.0	32
107	Initial Evaluation of AF78: a Rationally Designed Fluorine-18-Labelled PET Radiotracer Targeting Norepinephrine Transporter. Molecular Imaging and Biology, 2020, 22, 602-611.	1.3	11
108	Prospective Comparison of PET Imaging with PSMA-Targeted ¹⁸F-DCFPyL Versus Na¹⁸F for Bone Lesion Detection in Patients with Metastatic Prostate Cancer. Journal of Nuclear Medicine, 2020, 61, 183-188.	2.8	27

#	Article	IF	Citations
109	Black-blood cinematic rendering: A new method for cardiac CT intraluminal visualization. Journal of Cardiovascular Computed Tomography, 2020, 14, 272-274.	0.7	19
110	Initial experience with 3D CT cinematic rendering of acute pancreatitis and associated complications. Abdominal Radiology, 2020, 45, 1290-1298.	1.0	11
111	Theranostics: Leveraging Molecular Imaging and Therapy to Impact Patient Management and Secure the Future of Nuclear Medicine. Journal of Nuclear Medicine, 2020, 61, 311-318.	2.8	40
112	Letter to the Editor re: â€œSemiquantitative Parameters in PSMA-Targeted PET Imaging with [18F]DCFPyL: Impact of Tumor Burden on Normal Organ Uptakeâ€• Molecular Imaging and Biology, 2020, 22, 19-21.	1.3	0
113	Online Prostate-Specific Membrane Antigen and Positron Emission Tomographyâ€“Guided Radiation Therapy for Oligometastatic Prostate Cancer. Advances in Radiation Oncology, 2020, 5, 260-268.	0.6	13
114	¹⁸F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging. Theranostics, 2020, 10, 1-16.	4.6	117
115	Disrupting Alzheimerâ€™s With Technology: Using Data to Forge a Solution. Journal of the American College of Radiology, 2020, 17, 327-329.	0.9	0
116	Found in Translation: Unpacking the Artificial Intelligence Revolution That Has Already Arrived. Journal of the American College of Radiology, 2020, 17, 1307-1308.	0.9	0
117	The prostate-specific membrane antigen (PSMA)-targeted radiotracer 18F-DCFPyL detects tumor neovasculature in metastatic, advanced, radioiodine-refractory, differentiated thyroid cancer. Medical Oncology, 2020, 37, 98.	1.2	9
118	Incidental primary breast cancer detected on surveillance 68Ga-DOTATATE PET/CT in a patient with metastatic neuroendocrine carcinoma. Radiology Case Reports, 2020, 15, 1344-1347.	0.2	6
119	Evaluation of Musculoskeletal and Pulmonary Bacterial Infections With [¹²⁴I]FIAU PET/CT. Molecular Imaging, 2020, 19, 153601212093687.	0.7	11
120	Mapping Your Career in the Era of Artificial Intelligence: Itâ€™s Up to You, Not Google. Journal of the American College of Radiology, 2020, 17, 1537-1538.	0.9	2
121	Histologic Validation of ¹⁸F-DCFPyL PET/CT with Comparison to Multiparametric MRI in Biochemically Recurrent Prostate Cancer. Radiology, 2020, 296, 573-574.	3.6	0
122	Prospective evaluation of 68Ga-PSMA-11 PET/CT in Chinese men with biochemical recurrence after radical prostatectomy for prostate cancer: relationships between location of recurrence, time after prostatectomy, and serum PSA level. Medical Oncology, 2020, 37, 89.	1.2	5
123	Recent updates and developments in PET imaging of prostate cancer. Abdominal Radiology, 2020, 45, 4063-4072.	1.0	8
124	â€œA Thyroid Surprise in the Quest for Prostate Cancerâ€• Clinical Thyroidology, 2020, 32, 196-198.	0.0	1
125	A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS). BMC Cancer, 2020, 20, 492.	1.1	16
126	¹¹C-PABA as a PET Radiotracer for Functional Renal Imaging: Preclinical and First-in-Human Study. Journal of Nuclear Medicine, 2020, 61, 1665-1671.	2.8	11

#	Article	IF	Citations
127	Imaging in Therapy Response Assessment and Surveillance of Lung Cancer: Evidenced-based Review With Focus on the Utility of 18F-FDG PET/CT. Clinical Lung Cancer, 2020, 21, 485-497.	1.1	10
128	⁶⁸Ga-PSMA PET/CT Combined with PET/Ultrasound-Guided Prostate Biopsy Can Diagnose Clinically Significant Prostate Cancer in Men with Previous Negative Biopsy Results. Journal of Nuclear Medicine, 2020, 61, 1314-1319.	2.8	47
129	Dynamic imaging in patients with tuberculosis reveals heterogeneous drug exposures in pulmonary lesions. Nature Medicine, 2020, 26, 529-534.	15.2	87
130	The Accidental Consequences of Student Debt. Journal of the American College of Radiology, 2020, 17, 557-559.	0.9	0
131	The Future of Digital Communication: Improved Messaging Context, Artificial Intelligence, and Your Privacy. Journal of the American College of Radiology, 2020, 17, 821-823.	0.9	0
132	Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer. JAMA Oncology, 2020, 6, 650.	3.4	696
133	Appropriate Use Criteria for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer After Definitive Primary Treatment. Journal of Nuclear Medicine, 2020, 61, 552-562.	2.8	10
134	Prostate-specific membrane antigen (PSMA) imaging: the past is prologue and the future is scintillating. Translational Andrology and Urology, 2020, 9, 840-842.	0.6	0
135	Health Care Transformation From the Outside In. Journal of the American College of Radiology, 2020, 17, 979-980.	0.9	1
136	Prostate Specific Antigen and Prostate Specific Antigen Doubling Time Predict Findings on 18 F-DCFPyL Positron Emission Tomography/Computerized Tomography in Patients with Biochemically Recurrent Prostate Cancer. Journal of Urology, 2020, 204, 496-502.	0.2	12
137	A prospective phase II/III multicenter study of PSMA-targeted 18F-DCFPyL PET/CT imaging in patients with prostate cancer (OSPREY): A sub-analysis of regional and distant metastases detection rates at initial staging by 18F-DCFPyL PET/CT.. Journal of Clinical Oncology, 2020, 38, 9-9.	0.8	10
138	Enhancement of Radiotherapy with Human Mesenchymal Stem Cells Containing Gold Nanoparticles. Tomography, 2020, 6, 373-378.	0.8	4
139	A phase II randomized trial of RAdium-223 dichloride and SABR versus SABR for oligomEtastatic prostate caNcerS (RAVENS).. Journal of Clinical Oncology, 2020, 38, TPS5586-TPS5586.	0.8	1
140	A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).. Journal of Clinical Oncology, 2020, 38, 116-116.	0.8	1
141	What Health Care Can Learn FromÂSelf-Driving Vehicles. Journal of the American College of Radiology, 2019, 16, 261-263.	0.9	2
142	What the radiologist needs to know: the role of preoperative computed tomography in selection of operative approach for adrenalectomy and review of operative techniques. Abdominal Radiology, 2019, 44, 140-153.	1.0	6
143	Incidentally Detected ¹⁸F-FDG-Avid Prostate Cancer Diagnosed Using a Novel Fusion Biopsy Platform. Journal of Endourology Case Reports, 2019, 5, 68-70.	0.3	1
144	Imager-4D: New Software for Viewing Dynamic PET Scans and Extracting Radiomic Parameters from PET Data. Journal of Digital Imaging, 2019, 32, 1071-1080.	1.6	5

#	Article	IF	Citations
145	Can the interplay between androgen signaling and PSMA expression be leveraged for theranostic applications?. Translational Andrology and Urology, 2019, 8, S263-S264.	0.6	6
146	CXCR4-Directed Imaging in Solid Tumors. Frontiers in Oncology, 2019, 9, 770.	1.3	47
147	The application of cinematic rendering to CT evaluation of upper tract urothelial tumors: principles and practice. Abdominal Radiology, 2019, 44, 3886-3892.	1.0	11
148	Imaging CAR T cell therapy with PSMA-targeted positron emission tomography. Science Advances, 2019, 5, eaaw5096.	4.7	87
149	Recent Updates on Molecular Imaging Reporting and Data Systems (MI-RADS) for Theranostic Radiotracersâ€"Navigating Pitfalls of SSTR- and PSMA-Targeted PET/CT. Journal of Clinical Medicine, 2019, 8, 1060.	1.0	20
150	Enhancing CAR T-cell therapy through cellular imaging and radiotherapy. Lancet Oncology, The, 2019, 20, e443-e451.	5.1	66
151	A pilot study of prostateâ€specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer. Prostate, 2019, 79, 1597-1603.	1.2	18
152	[68Ga]-Pentixafor PET/CT for CXCR4-Mediated Imaging of Vestibular Schwannomas. Frontiers in Oncology, 2019, 9, 503.	1.3	15
153	Radioimmunoimaging and Targeted Therapy. , 2019, , 201-214.		0
154	The Value of Reputation: Understanding the Current Marketing Ecosystem for Content Producers. Journal of the American College of Radiology, 2019, 16, 1509-1510.	0.9	0
155	Learning to Talk Again in a Voice-First World. Journal of the American College of Radiology, 2019, 16, 1123-1124.	0.9	1
156	Imaging of Prostate-Specific Membrane Antigen with Small-Molecule PET Radiotracers: From the Bench to Advanced Clinical Applications. Annual Review of Medicine, 2019, 70, 461-477.	5.0	50
157	Three-dimensional computed tomography cinematic rendering of mandibular odontogenic myxofibroma. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2019, 128, e122-e125.	0.2	5
158	Preoperative PSMAâ€targeted PET imaging: more than just a tool for prostate cancer staging?. BJU International, 2019, 124, 2-3.	1.3	1
159	Cinematic rendering of skin and subcutaneous soft tissues: potential applications in acute trauma. Emergency Radiology, 2019, 26, 573-580.	1.0	10
160	Improved identification of patients with oligometastatic clearÂcell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT. Annals of Nuclear Medicine, 2019, 33, 617-623.	1.2	40
161	The next era of renal radionuclide imaging: novel PET radiotracers. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1773-1786.	3.3	32
162	Relationship between DXA measured metrics of adiposity and glucose homeostasis; An analysis of the NHANES data. PLoS ONE, 2019, 14, e0216900.	1.1	3

#	Article	IF	Citations
163	14.3 OPPORTUNITIES IN PRECISION PSYCHIATRY USING PET-BASED NEUROIMAGING. Schizophrenia Bulletin, 2019, 45, S111-S112.	2.3	0
164	Soft Tissue Calcinosis Universalis Visualized with Novel 3-D Computed Tomography Cinematic Rendering. Journal of Rheumatology, 2019, 46, 539-540.	1.0	5
165	Cinematic Rendering of Neurofibromatosis Type I Gastrointestinal Stromal Tumors. Radiology, 2019, 291, 298-298.	3.6	4
166	Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer: An Update on Important Pitfalls. Seminars in Nuclear Medicine, 2019, 49, 255-270.	2.5	81
167	18F-NaF-PET/CT for the detection of bone metastasis in prostate cancer: a meta-analysis of diagnostic accuracy studies. Annals of Nuclear Medicine, 2019, 33, 351-361.	1.2	50
168	Novel Structured Reporting Systems for Theranostic Radiotracers. Journal of Nuclear Medicine, 2019, 60, 577-584.	2.8	24
169	PSMA-targeted [18F]DCFPyL PET/CT-avid lesions in a patient with prostate cancer: Clinical decision-making informed by the PSMA-RADS interpretive framework. Urology Case Reports, 2019, 23, 72-74.	0.1	5
170	No Mission, No Engagement. Journal of the American College of Radiology, 2019, 16, 1504-1505.	0.9	0
171	From the Reading Room to the Courtroomâ€"The Use of Molecular Radionuclide Imaging in Criminal Trials. Journal of the American College of Radiology, 2019, 16, 1612-1617.	0.9	1
172	Impact of aging on semiquantitative uptake parameters in normal rated clinical baseline [123I]Ioflupane single photon emission computed tomography/computed tomography. Nuclear Medicine Communications, 2019, 40, 1001-1004.	0.5	5
173	Computed Tomography Cinematic Rendering in the Evaluation of Colonic Pathology. Journal of Computer Assisted Tomography, 2019, 43, 475-484.	0.5	14
174	Hereditary Spherocytosis Presenting as Diffuse Bone Marrow Activation and Splenomegaly on PSMA-Targeted 18F-DCFPyL PET/CT. Clinical Nuclear Medicine, 2019, 44, e313-e314.	0.7	3
175	Cinematic Rendering With Positive Oral Contrast: Virtual Fluoroscopy. Journal of Computer Assisted Tomography, 2019, 43, 718-720.	0.5	9
176	Inconsistent Detection of Sites of Metastatic Non-Clear Cell Renal Cell Carcinoma with PSMA-Targeted [18F]DCFPyL PET/CT. Molecular Imaging and Biology, 2019, 21, 567-573.	1.3	46
177	Volumetric and texture analysis of pretherapeutic 18F-FDG PET can predict overall survival in medullary thyroid cancer patients treated with Vandetanib. Endocrine, 2019, 63, 293-300.	1.1	13
178	Follow-up of Lesions with Equivocal Radiotracer Uptake on PSMA-Targeted PET in Patients with Prostate Cancer: Predictive Values of the PSMA-RADS-3A and PSMA-RADS-3B Categories. Journal of Nuclear Medicine, 2019, 60, 511-516.	2.8	29
179	Impact of Tumor Burden on Quantitative [68Ga] DOTATOC Biodistribution. Molecular Imaging and Biology, 2019, 21, 790-798.	1.3	10
180	Simplifying Complexity: Lessons for Radiology From a New Type of Stock Exchange. Journal of the American College of Radiology, 2019, 16, 536-538.	0.9	1

#	Article	IF	Citations
181	Moving into the next era of PET myocardial perfusion imaging: introduction of novel 18F-labeled tracers. International Journal of Cardiovascular Imaging, 2019, 35, 569-577.	0.7	32
182	Diagnostic performance of ¹⁸F-DCFPyL in the OSPREY Trial: A prospective phase 2/3 multicenter study of ¹⁸F-DCFPyL PET/CT imaging in patients (Pts) with known or suspected metastatic prostate cancer (mPC).. Journal of Clinical Oncology, 2019, 37, 5012-5012.	0.8	3
183	A phase III, multicenter study to assess the diagnostic performance and clinical impact of 18F-DCFPyL PET/CT in men with suspected recurrence of prostate cancer (CONDOR).. Journal of Clinical Oncology, 2019, 37, TPS5093-TPS5093.	0.8	4
184	Uptake of prostate-specific membrane antigen-targeted 18F-DCFPyL in avascular necrosis of the femoral head. World Journal of Nuclear Medicine, 2019, 18, 416-419.	0.3	3
185	Vas deferens infiltration by prostate cancer on prostate-specific membrane antigen-targeted 18F-DCFPyL positron emission tomography/computed tomography: A unique visual pattern. World Journal of Nuclear Medicine, 2019, 18, 424-427.	0.3	2
186	Deep learning algorithm improves identification of men with low-risk prostate cancer using PSMA-targeted ^{99m}Tc-MIP-1404 SPECT/CT.. Journal of Clinical Oncology, 2019, 37, e16572-e16572.	0.8	0
187	Imaging of prostate cancer with positron emission tomography. Clinical Advances in Hematology and Oncology, 2019, 17, 455-463.	0.3	7
188	Initial experience with cinematic rendering for chest cardiovascular imaging. British Journal of Radiology, 2018, 91, 20170558.	1.0	35
189	Combined model-based and patient-specific dosimetry for 18F-DCFPyL, a PSMA-targeted PET agent. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 989-998.	3.3	12
190	Evaluation of Kawasakiâ€™s disease-associated coronary artery aneurysms with 3D CT cinematic rendering. Emergency Radiology, 2018, 25, 449-453.	1.0	12
191	Photorealistic 3-Dimensional Cinematic Rendering of Clear Cell Renal Cell Carcinoma From Volumetric Computed Tomography Data. Urology, 2018, 115, e3-e5.	0.5	11
192	A Voice From the Past: Rediscovering the Virchow Node With Prostate-specific Membrane Antigen-targeted 18 F-DCFPyL Positron Emission Tomography Imaging. Urology, 2018, 117, 18-21.	0.5	16
193	3D cinematic rendering of the calvarium, maxillofacial structures, and skull base: preliminary observations. British Journal of Radiology, 2018, 91, 20170826.	1.0	17
194	MDCT of ductus diverticulum: 3D cinematic rendering to enhance understanding of anatomic configuration and avoid misinterpretation as traumatic aortic injury. Emergency Radiology, 2018, 25, 209-213.	1.0	20
195	Flare on Serial Prostate-Specific Membrane Antigenâ€“Targeted 18F-DCFPyL PET/CT Examinations in Castration-Resistant Prostate Cancer. Clinical Nuclear Medicine, 2018, 43, 213-216.	0.7	14
196	Molecular Imaging of Prostate Cancer: Choosing the Right Agent. Journal of Nuclear Medicine, 2018, 59, 787-788.	2.8	4
197	^{99m}Tc-sestamibi SPECT/CT for the characterization of renal masses: a pictorial guide. British Journal of Radiology, 2018, 91, 20170526.	1.0	15
198	Diagnosing small bowel carcinoid tumor in a patient with oligometastatic prostate cancer imaged with PSMA-Targeted [18 F]DCFPyL PET/CT: Value of the PSMA-RADS-3D Designation. Urology Case Reports, 2018, 17, 22-25.	0.1	7

#	Article	IF	Citations
199	Fetal and placental anatomy visualized with cinematic rendering from volumetric CT data. Radiology Case Reports, 2018, 13, 281-283.	0.2	9
200	Functional Renal Imaging with 2-Deoxy-2-¹⁸F-Fluorosorbitol PET in Rat Models of Renal Disorders. Journal of Nuclear Medicine, 2018, 59, 828-832.	2.8	26
201	The role of molecular imaging in the characterization of renal masses. Current Opinion in Urology, 2018, 28, 159-165.	0.9	12
202	Cinematic rendering of small bowel pathology: preliminary observations from this novel 3D CT visualization method. Abdominal Radiology, 2018, 43, 2928-2937.	1.0	17
203	SSTR-RADS Version 1.0 as a Reporting System for SSTR PET Imaging and Selection of Potential PRRT Candidates: A Proposed Standardization Framework. Journal of Nuclear Medicine, 2018, 59, 1085-1091.	2.8	58
204	Imaging of Nonprostate Cancers Using PSMA-Targeted Radiotracers: Rationale, Current State of the Field, and a Call to Arms. Journal of Nuclear Medicine, 2018, 59, 871-877.	2.8	115
205	Low levels of PSMA expression limit the utility of 18F-DCFPyL PET/CT for imaging urothelial carcinoma. Annals of Nuclear Medicine, 2018, 32, 69-74.	1.2	28
206	Low-Level Endogenous PSMA Expression in Nonprostatic Tumor Xenografts Is Sufficient for In Vivo Tumor Targeting and Imaging. Journal of Nuclear Medicine, 2018, 59, 486-493.	2.8	27
207	Predictive Value of ¹⁸F-FDG PET in Patients with Advanced Medullary Thyroid Carcinoma Treated with Vandetanib. Journal of Nuclear Medicine, 2018, 59, 756-761.	2.8	26
208	The distribution of the alpha7 nicotinic acetylcholine receptor in healthy aging: An in vivo positron emission tomography study with [18F]ASEM. NeuroImage, 2018, 165, 118-124.	2.1	27
209	CT evaluation of musculoskeletal trauma: initial experience with cinematic rendering. Emergency Radiology, 2018, 25, 93-101.	1.0	50
210	Proposal for a Structured Reporting System for Prostate-Specific Membrane Antigenâ€“Targeted PET Imaging: PSMA-RADS Version 1.0. Journal of Nuclear Medicine, 2018, 59, 479-485.	2.8	122
211	Use of quantitative SPECT/CT reconstruction in 99mTc-sestamibi imaging of patients with renal masses. Annals of Nuclear Medicine, 2018, 32, 87-93.	1.2	17
212	Coronary artery to pulmonary artery fistula visualized with 3D cinematic rendering. Journal of Cardiovascular Computed Tomography, 2018, 12, 166-167.	0.7	9
213	Cinematic rendering of cardiac CT volumetric data: Principles and initial observations. Journal of Cardiovascular Computed Tomography, 2018, 12, 56-59.	0.7	52
214	Complete biochemical response after stereotactic ablative radiotherapy of an isolated prostate cancer pelvic soft tissue recurrence detected by 18F-DCFPyL PET/CT. Urology Case Reports, 2018, 16, 86-88.	0.1	4
215	Use of 99m Tc-sestamibi Single-photon Emission Computed Tomography / X-ray Computed Tomography in the Diagnosis of Hybrid Oncocytic / Chromophobe Tumor in a Pediatric Patient. Urology, 2018, 113, 206-208.	0.5	5
216	PSMA-RADS Version 1.0: A Step Towards Standardizing the Interpretation and Reporting of PSMAâ€“targeted PET Imaging Studies. European Urology, 2018, 73, 485-487.	0.9	108

#	Article	IF	Citations
217	Prostate Specific Membrane Antigen Targeted ¹⁸ F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study. Journal of Urology, 2018, 199, 126-132.	0.2	86
218	Response to R-CHOP in HPV-related squamous cell carcinoma of base of tongue: a case report. Cancers of the Head & Neck, 2018, 3, 2.	6.2	4
219	Generative Adversarial Networks for the Creation of Realistic Artificial Brain Magnetic Resonance Images. Tomography, 2018, 4, 159-163.	0.8	68
220	Uptake of Prostate-Specific Membrane Antigenâ€“Targeted 18F-DCFPyL in Cerebral Radionecrosis. Clinical Nuclear Medicine, 2018, 43, e419-e421.	0.7	24
221	Molecular Imaging for Evaluation of Viable Testicular Cancer Nodal Metastases. Current Urology Reports, 2018, 19, 110.	1.0	9
222	The theranostic promise for Neuroendocrine Tumors in the late 2010s - Where do we stand, where do we go?. Theranostics, 2018, 8, 6088-6100.	4.6	59
223	Noninvasive ¹¹ C-rifampin positron emission tomography reveals drug biodistribution in tuberculous meningitis. Science Translational Medicine, 2018, 10, .	5.8	73
224	3D CT cinematic rendering of mycotic aneurysms. Emergency Radiology, 2018, 25, 723-728.	1.0	7
225	Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on ¹⁸F-DCFPyL PET/CT Imaging. Journal of Nuclear Medicine, 2018, 59, 1857-1864.	2.8	43
226	3D CT of renal pathology: initial experience with cinematic rendering. Abdominal Radiology, 2018, 43, 3445-3455.	1.0	13
227	Launching a Successful Startup: AnÂEntrepreneurâ€™s Field Guide. Journal of the American College of Radiology, 2018, 15, 1521-1522.	0.9	2
228	Evaluation of Stomach Neoplasms With 3-Dimensional Computed Tomography. Journal of Computer Assisted Tomography, 2018, 42, 661-666.	0.5	21
229	Imaging Prostate Cancer With Prostate-Specific Membrane Antigen PET/CT and PET/MRI: Current and Future Applications. American Journal of Roentgenology, 2018, 211, 286-294.	1.0	25
230	Brodifacoum-contaminated synthetic marijuana: clinical and radiologic manifestations of a public health outbreak causing life-threatening coagulopathy. Emergency Radiology, 2018, 25, 715-718.	1.0	12
231	The emerging role of imaging in prostate cancer secondary screening: multiparametric magnetic resonance imaging and the incipient incorporation of molecular imaging. British Journal of Radiology, 2018, 91, 20170960.	1.0	1
232	The Incipient Digital Revolution in Hospitality and Health Care: DigitalÂIs Hospitable. Journal of the American College of Radiology, 2018, 15, 1351-1353.	0.9	2
233	Meet Generation Z: Top 10 Trends of 2018. Journal of the American College of Radiology, 2018, 15, 1791-1793.	0.9	12
234	From validity to clinical utility: the influence of circulating tumor <scp>DNA</scp> on melanoma patient management in a realâ€world setting. Molecular Oncology, 2018, 12, 1661-1672.	2.1	32

#	Article	IF	Citations
235	SPECT vs. PET in cardiac innervation imaging: clash of the titans. Clinical and Translational Imaging, 2018, 6, 293-303.	1.1	19
236	Molecular imaging reporting and data systems (MI-RADS): a generalizable framework for targeted radiotracers with theranostic implications. Annals of Nuclear Medicine, 2018, 32, 512-522.	1.2	37
237	Spontaneous Regression of a Low-Grade Renal Cell Carcinoma With Oncocytic Features After Renal Mass Biopsy. Clinical Genitourinary Cancer, 2018, 16, e1083-e1085.	0.9	6
238	PSMA-Targeted 18F-DCFPyL PET/CT Imaging of Clear Cell Renal Cell Carcinoma: Results from a Rapid Autopsy. European Urology, 2017, 71, 145-146.	0.9	40
239	Clinical Applications of Molecular Imaging in the Management of Prostate Cancer. PET Clinics, 2017, 12, 185-192.	1.5	12
240	Surgical histopathology for suspected oncocytoma on renal mass biopsy: a systematic review and metaâ€analysis. BJU International, 2017, 119, 661-666.	1.3	71
241	Renal Pseudoaneurysm Mimicking Local Cancer Recurrence After Partial Nephrectomy. Urology Case Reports, 2017, 11, 1-3.	0.1	2
242	Clinical Experience with 18F-Labeled Small Molecule Inhibitors of Prostate-Specific Membrane Antigen. PET Clinics, 2017, 12, 235-241.	1.5	13
243	Simplifying volumesâ€ofâ€interest (VOIs) definition in quantitative SPECT: Beyond manual definition of 3D wholeâ€organ VOIs. Medical Physics, 2017, 44, 1707-1717.	1.6	14
244	Diagnostic Value of¹⁸F-FDG PET/CT Versus MRI in the Setting of Antibody-Specific Autoimmune Encephalitis. Journal of Nuclear Medicine, 2017, 58, 1307-1313.	2.8	108
245	Challenges in Quality Improvement: Appropriate Utilization of Computed Tomography Angiograms for Evaluation of Pulmonary Embolism. American Journal of Medicine, 2017, 130, 652-656.	0.6	1
246	Oligoprogression. Academic Radiology, 2017, 24, 898-900.	1.3	7
247	Imaging of Prostate-Specific Membrane Antigen Using [18F]DCFPyL. PET Clinics, 2017, 12, 289-296.	1.5	23
248	Semiquantitative Parameters in PSMA-Targeted PET Imaging with ¹⁸F-DCFPyL: Variability in Normal-Organ Uptake. Journal of Nuclear Medicine, 2017, 58, 942-946.	2.8	38
249	Whole-Body ¹⁸F-FDG PET and ¹⁸F-FDG PET/CT in Patients with Suspected Paraneoplastic Syndrome: A Systematic Review and Meta-Analysis of Diagnostic Accuracy. Journal of Nuclear Medicine, 2017, 58, 1031-1036.	2.8	31
250	Molecular imaging of advanced thyroid cancer: iodinated radiotracers and beyond. Medical Oncology, 2017, 34, 189.	1.2	9
251	PSMA: a potential therapeutic target in RCC. Nature Reviews Urology, 2017, 14, 646-647.	1.9	15
252	An Unusual Case of Penile Prostate Cancer Uncovered by Multiparametric MRI and PSMA-Targeted 18F-DCFPyL PET/CT. Clinical Nuclear Medicine, 2017, 42, e441-e443.	0.7	1

#	Article	IF	Citations
253	Oligometastatic prostate cancer. Current Opinion in Urology, 2017, 27, 533-541.	0.9	30
254	Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy. Journal of Nuclear Medicine, 2017, 58, 67S-76S.	2.8	163
255	Prostate-Specific Membrane Antigenâ€“Targeted Imaging With [18F]DCFPyL in High-Grade Gliomas. Clinical Nuclear Medicine, 2017, 42, e433-e435.	0.7	49
256	Defining the clinical utility of PSMAâ€targeted PET imaging of prostate cancer. BJU International, 2017, 120, 160-161.	1.3	3
257	Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2117-2136.	3.3	234
258	Evaluation of a Large Renal Mass Using 99mTc-MIBI SPECT/CT in a Patient With Chronic Kidney Disease. Clinical Nuclear Medicine, 2017, 42, e166-e167.	0.7	0
259	Image Processing from 2D to 3D. Medical Radiology, 2017, , 103-120.	0.0	7
260	Prostate Cancer Local Recurrence Detected With Both 18 F-Fluciclovine and PSMA-targeted 18 F-DCFPyL PET/CT. Urology, 2017, 107, e9-e10.	0.5	8
261	Reproductive history and fracture risk in postmenopausal women in a US national survey. Journal of Family Planning and Reproductive Health Care, 2017, 43, 242.1-243.	0.9	1
262	PSMA Ligands for PET Imaging of Prostate Cancer. Journal of Nuclear Medicine, 2017, 58, 1545-1552.	2.8	165
263	A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE). BMC Cancer, 2017, 17, 453.	1.1	83
264	Incidental pulmonary arterial dilatation and coronary calcifications in patients with hypertension and normal findings on myocardial perfusion technetiumâ€99m sestamibi singleâ€photon emission computed tomography. Journal of Clinical Hypertension, 2017, 19, 1054-1055.	1.0	1
265	Characterization of indeterminate renal masses with molecular imaging: how do we turn potential into reality?. EJNMMI Research, 2017, 7, 34.	1.1	10
266	Correlation of PSMA-Targeted 18F-DCFPyL PET/CT Findings With Immunohistochemical and Genomic Data in a Patient With Metastatic Neuroendocrine Prostate Cancer. Clinical Genitourinary Cancer, 2017, 15, e65-e68.	0.9	61
267	Correlation of 99mTc-sestamibi uptake in renal masses with mitochondrial content and multi-drug resistance pump expression. EJNMMI Research, 2017, 7, 80.	1.1	33
268	Patterns of uptake of prostate-specific membrane antigen (PSMA)-targeted 18F-DCFPyL in peripheral ganglia. Annals of Nuclear Medicine, 2017, 31, 696-702.	1.2	34
269	Appearance of adrenal myelolipomas on 2-deoxy-2-(18F) fluoro-D-glucose positron emission tomography-computed tomography. World Journal of Nuclear Medicine, 2017, 16, 271.	0.3	7
270	Plasma Fluoride Level and Femoral Bone Mineral Density in Post-Menopausal Women. International Journal of Occupational and Environmental Medicine, 2017, 8, 56-57.	4.1	0

#	Article	IF	Citations
271	A phase II randomized trial of observation versus stereotactic ablative radiation for oligometastatic prostate cancer (ORIOLE).. Journal of Clinical Oncology, 2017, 35, TPS5094-TPS5094.	0.8	0
272	PSMAâ€targeted imaging of prostate cancer: the best is yet to come. BJU International, 2016, 117, 715-716.	1.3	22
273	Detection of 18F-FDG PET/CT Occult Lesions With 18F-DCFPyL PET/CT in a Patient With Metastatic Renal Cell Carcinoma. Clinical Nuclear Medicine, 2016, 41, 83-85.	0.7	48
274	PSMA-Based [18F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer. Molecular Imaging and Biology, 2016, 18, 411-419.	1.3	202
275	Initial Preclinical Evaluation of ¹⁸F-Fluorodeoxysorbitol PET as a Novel Functional Renal Imaging Agent. Journal of Nuclear Medicine, 2016, 57, 1625-1628.	2.8	26
276	Noninvasive determination of renal tumor histology utilizing molecular imaging. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 525-528.	0.8	8
277	Prostate-Specific Membrane Antigenâ€“Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer. Journal of Nuclear Medicine, 2016, 57, 90S-96S.	2.8	48
278	Liposarcoma metastases to the small bowel presenting as fat-density intraluminal lesions. Radiology Case Reports, 2016, 11, 296-298.	0.2	0
279	Computed Tomography Appearance of Surgically Resected Adrenal Hematomas. Journal of Computer Assisted Tomography, 2016, 40, 892-895.	0.5	3
280	PSMA-Based Detection of Prostate Cancer Bone Lesions With 18F-DCFPyL PET/CT: A Sensitive Alternative to 99mTc-MDP Bone Scan and Na18F PET/CT?. Clinical Genitourinary Cancer, 2016, 14, e115-e118.	0.9	50
281	Advances in the Treatment of Oligometastatic Disease:. Academic Radiology, 2016, 23, 326-328.	1.3	3
282	CT Appearance of Adrenal Cystic Lymphangioma: Radiologic-Pathologic Correlation. American Journal of Roentgenology, 2016, 206, 81-85.	1.0	13
283	Prospective Evaluation of 99mTc-sestamibi SPECT/CT for the Diagnosis of Renal Oncocytomas and Hybrid Oncocytic/Chromophobe Tumors. European Urology, 2016, 69, 413-416.	0.9	121
284	Comparison of Prostate-Specific Membrane Antigenâ€“Based ¹⁸F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-NaÃ¯ve and Castration-Resistant Metastatic Prostate Cancer. Journal of Nuclear Medicine, 2016, 57, 46-53.	2.8	111
285	[64Cu]XYIMSR-06: A dual-motif CAIX ligand for PET imaging of clear cell renal cell carcinoma. Oncotarget, 2016, 7, 56471-56479.	0.8	49
286	Study of PSMA-targeted 18F-DCFPyL PET/CT in the evaluation of men with an elevated PSA following radical prostatectomy.. Journal of Clinical Oncology, 2016, 34, 299-299.	0.8	0
287	Oncocytic Neoplasm on Renal Mass Biopsy: A Diagnostic Conundrum. Oncology, 2016, 30, 426-35.	0.4	6
288	Angiomyolipoma with epithelial cysts: Add one to the differential of cystic renal lesions. International Journal of Urology, 2015, 22, 1081-1082.	0.5	5

#	Article	IF	Citations
289	Nuclear imaging of renal tumours: a step towards improved risk stratification. Nature Reviews Urology, 2015, 12, 445-450.	1.9	13
290	Initial Experience Using 99mTc-MIBI SPECT/CT for the Differentiation of Oncocytoma From Renal Cell Carcinoma. Clinical Nuclear Medicine, 2015, 40, 309-313.	0.7	60
291	Initial Evaluation of [18F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer. Molecular Imaging and Biology, 2015, 17, 565-574.	1.3	378
292	Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT. Annals of Nuclear Medicine, 2015, 29, 877-882.	1.2	152
293	¹⁸F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer. Journal of Nuclear Medicine, 2015, 56, 1003-1010.	2.8	180
294	Repeatability of Radiotracer Uptake in Normal Abdominal Organs with ¹¹¹In-Pentetreotide Quantitative SPECT/CT. Journal of Nuclear Medicine, 2015, 56, 985-988.	2.8	7
295	Uptake of [18F]DCFPyL in Paget's Disease of Bone, an Important Potential Pitfall in the Clinical Interpretation of PSMA PET Studies. Tomography, 2015, 1, 81-84.	0.8	31
296	Imaging of carbonic anhydrase IX with an 111In-labeled dual-motif inhibitor. Oncotarget, 2015, 6, 33733-33742.	0.8	44
297	The Role of PET in the Evaluation of Musculoskeletal Infections. Seminars in Musculoskeletal Radiology, 2014, 18, 166-174.	0.4	8
298	The Key Image and Case Log Application. Academic Radiology, 2014, 21, 916-930.	1.3	10